Drug news
Cardinal Health to distribute Amyvid diagnostic imaging agent for Alzheimer's Disease
Cardinal Health will manufacture and distribute Amyvid (florbetapir F18) the new diagnostic imaging agent from Eli Lilly and Company that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline. The commercial launch of Amyvid is scheduled for June 1, 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.